{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-010140","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.052757+00:00","generated_at":"2026-05-15T08:24:35.629611+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reviva reports FY2025 net loss of $19.9M; FDA requires second Phase 3 trial for schizophrenia drug","bullets":["Net loss of $19.9M ($5.48 per share) vs $29.9M ($17.73) in FY2024.","Cash and equivalents $14.4M at Dec 31, 2025; ~$23M after March 2026 offering, funding into Q1-2027.","FDA recommended a second Phase 3 trial (RECOVER-2) for brilaroxazine in schizophrenia; initiation planned mid-2026.","Positive 1-year open-label extension data: sustained efficacy, benign weight gain (~1.5 kg), no motor side effects.","Completed public offerings totaling $29M in 2025 and early 2026; intends to fund RECOVER-2 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-010140","json":"https://secwatch.observer/filing/0001437749-26-010140.json","markdown":"https://secwatch.observer/filing/0001437749-26-010140.md","text":"https://secwatch.observer/filing/0001437749-26-010140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/0001437749-26-010140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/rvph20260313_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:24:35.629611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f998c7ab69be7554d1ddab285bff747cdee33c9","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/0001437749-26-010140-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}